Controversial Duchenne MD player Solid Bio takes another hit, laying off staffers in a bid to weather FDA hold
With their gene therapy program for Duchenne muscular dystrophy frozen in regulatory limbo with no evident sign of a near-term thaw, Solid Biosciences $SLDB is axing staff, bidding top execs goodbye and circling the wagons in a bid to survive the storm.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
